Assessment of systemic vasculitis

Anne Miller, Neil Basu, Raashid Luqmani*

*Corresponding author for this work

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The systemic vasculitides are an uncommon group of autoimmune diseases capable of causing multi organ failure and death. Current immunosuppressive strategies have substantially improved the outcome, but the natural history of treated disease is unstable, typically characterised by frequent relapses, drug toxicity and an increasing burden of damage. Early diagnosis, accurate staging and regular evaluation of disease status are important in the management of the vasculitides. Clinical evaluation tools have been developed and provide a comprehensive assessment of patients. Serological markers, especially anti-neutrophil cytoplasm antibody (ANCA), pathology and imaging investigations are a useful addition, but are more valuable in diagnosis rather than monitoring of disease activity. Advances in magnetic resonance imaging in large vessel vasculitis have improved our ability to characterise disease and may lead to earlier diagnosis and better control in future. Development of new biomarkers is required in vasculitis, and this is likely to advance our understanding as well as the management of these complex conditions.
Original languageEnglish
Pages (from-to)170-175
Number of pages6
JournalAutoimmunity Reviews
Volume8
Issue number2
Early online date29 Jul 2008
DOIs
Publication statusPublished - Dec 2008
EventCongress on Infections, Rheumatism and Autoimmunity - Milan, Italy
Duration: 6 Mar 20088 Mar 2008

Fingerprint

Systemic Vasculitis
Vasculitis
Early Diagnosis
Immunosuppressive Agents
Drug-Related Side Effects and Adverse Reactions
Natural History
Autoimmune Diseases
Cytoplasm
Neutrophils
Biomarkers
Magnetic Resonance Imaging
Pathology
Recurrence
Antibodies

Keywords

  • BVAS
  • disease-activity
  • Takayasus-arteritis
  • duplex ultrasonography
  • VDI
  • Wegeners-granulomatosis
  • ANCA-associated vasculitis
  • systemic vasculitis
  • giant-cell arteritis
  • classification
  • ANCA
  • diagnosis
  • imaging
  • antineutrophil cytoplasmic autoantibodies
  • temporal arteritis
  • antineutrophil cytoplasmic antibodies, Humans, Quality of Life, Systemic Vasculitis, Imaging, ANCA, BVAS, VDI

Cite this

Assessment of systemic vasculitis. / Miller, Anne; Basu, Neil; Luqmani, Raashid.

In: Autoimmunity Reviews, Vol. 8, No. 2, 12.2008, p. 170-175.

Research output: Contribution to journalArticle

Miller, A, Basu, N & Luqmani, R 2008, 'Assessment of systemic vasculitis', Autoimmunity Reviews, vol. 8, no. 2, pp. 170-175. https://doi.org/10.1016/j.autrev.2008.07.001
Miller, Anne ; Basu, Neil ; Luqmani, Raashid. / Assessment of systemic vasculitis. In: Autoimmunity Reviews. 2008 ; Vol. 8, No. 2. pp. 170-175.
@article{7cc1699fb312414dbc282fe7fb06e70b,
title = "Assessment of systemic vasculitis",
abstract = "The systemic vasculitides are an uncommon group of autoimmune diseases capable of causing multi organ failure and death. Current immunosuppressive strategies have substantially improved the outcome, but the natural history of treated disease is unstable, typically characterised by frequent relapses, drug toxicity and an increasing burden of damage. Early diagnosis, accurate staging and regular evaluation of disease status are important in the management of the vasculitides. Clinical evaluation tools have been developed and provide a comprehensive assessment of patients. Serological markers, especially anti-neutrophil cytoplasm antibody (ANCA), pathology and imaging investigations are a useful addition, but are more valuable in diagnosis rather than monitoring of disease activity. Advances in magnetic resonance imaging in large vessel vasculitis have improved our ability to characterise disease and may lead to earlier diagnosis and better control in future. Development of new biomarkers is required in vasculitis, and this is likely to advance our understanding as well as the management of these complex conditions.",
keywords = "BVAS, disease-activity, Takayasus-arteritis, duplex ultrasonography, VDI, Wegeners-granulomatosis, ANCA-associated vasculitis, systemic vasculitis, giant-cell arteritis, classification, ANCA, diagnosis, imaging, antineutrophil cytoplasmic autoantibodies, temporal arteritis, antineutrophil cytoplasmic antibodies, Humans, Quality of Life, Systemic Vasculitis, Imaging, ANCA, BVAS, VDI",
author = "Anne Miller and Neil Basu and Raashid Luqmani",
year = "2008",
month = "12",
doi = "10.1016/j.autrev.2008.07.001",
language = "English",
volume = "8",
pages = "170--175",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Assessment of systemic vasculitis

AU - Miller, Anne

AU - Basu, Neil

AU - Luqmani, Raashid

PY - 2008/12

Y1 - 2008/12

N2 - The systemic vasculitides are an uncommon group of autoimmune diseases capable of causing multi organ failure and death. Current immunosuppressive strategies have substantially improved the outcome, but the natural history of treated disease is unstable, typically characterised by frequent relapses, drug toxicity and an increasing burden of damage. Early diagnosis, accurate staging and regular evaluation of disease status are important in the management of the vasculitides. Clinical evaluation tools have been developed and provide a comprehensive assessment of patients. Serological markers, especially anti-neutrophil cytoplasm antibody (ANCA), pathology and imaging investigations are a useful addition, but are more valuable in diagnosis rather than monitoring of disease activity. Advances in magnetic resonance imaging in large vessel vasculitis have improved our ability to characterise disease and may lead to earlier diagnosis and better control in future. Development of new biomarkers is required in vasculitis, and this is likely to advance our understanding as well as the management of these complex conditions.

AB - The systemic vasculitides are an uncommon group of autoimmune diseases capable of causing multi organ failure and death. Current immunosuppressive strategies have substantially improved the outcome, but the natural history of treated disease is unstable, typically characterised by frequent relapses, drug toxicity and an increasing burden of damage. Early diagnosis, accurate staging and regular evaluation of disease status are important in the management of the vasculitides. Clinical evaluation tools have been developed and provide a comprehensive assessment of patients. Serological markers, especially anti-neutrophil cytoplasm antibody (ANCA), pathology and imaging investigations are a useful addition, but are more valuable in diagnosis rather than monitoring of disease activity. Advances in magnetic resonance imaging in large vessel vasculitis have improved our ability to characterise disease and may lead to earlier diagnosis and better control in future. Development of new biomarkers is required in vasculitis, and this is likely to advance our understanding as well as the management of these complex conditions.

KW - BVAS

KW - disease-activity

KW - Takayasus-arteritis

KW - duplex ultrasonography

KW - VDI

KW - Wegeners-granulomatosis

KW - ANCA-associated vasculitis

KW - systemic vasculitis

KW - giant-cell arteritis

KW - classification

KW - ANCA

KW - diagnosis

KW - imaging

KW - antineutrophil cytoplasmic autoantibodies

KW - temporal arteritis

KW - antineutrophil cytoplasmic antibodies, Humans, Quality of Life, Systemic Vasculitis, Imaging, ANCA, BVAS, VDI

U2 - 10.1016/j.autrev.2008.07.001

DO - 10.1016/j.autrev.2008.07.001

M3 - Article

VL - 8

SP - 170

EP - 175

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 2

ER -